The interaction between antimicrobial and adjunctive therapies and the immune response to tuberculosis  by Wilkinson, R.
72 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
Type: Invited Presentation
Final Abstract Number: 36.001
Session: Tuberculosis: Hot Topics
Date: Saturday, April 5, 2014
Time: 15:45-17:45
Room: Room 1.40
Tuberculosis transmission oustide the home
R. Wood
Desmond Tutu HIV Foundation, Cape Town, South
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The history of tuberculosis has been viewed from the indus-
trialised world perspective. TB incidence peaked in the mid-19th
century and steadily decreased over the subsequent century. The
current world distribution of TB shows that incidence is greatest in
non-industrialised countries of sub-Saharan Africa and Asia. South
Africa and Swaziland currently have the highest TB burdens in the
world where more than 1% of their populations develop TB each
year. Cape Town is one of themost heavily TB burdened cities in the
world with more TB disease notiﬁed annually than the combined
numbers of USA, Canada and UK. A comparison of South African
and New York TB before chemotherapy demonstrates a 5- to 10-
fold decline in TB in New York due to social and environmental
factors, which did not occur in Cape Town. In addition to very high
TB rates among people living with HIV, HIV-negative individuals
living in Cape Town have similar TB burdens as reported a cen-
tury ago. We therefore went on to explore and quantify the social
and environmental locations and environmental factors maintain-
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HIV-1 infected patients co-infected with some pathogens are
at risk of developing of the immune reconstitution inﬂammatory
syndrome (IRIS) when initiating antiretroviral therapy (ART). IRIS
is characterized by inﬂammation leading to the clinical worsening
of a treated infection or the unmasking of a previously undiagnosed
condition or infection. It is commonly associated with tuberculosis
(TB), 8-43% of the HIV-TB co-infected patients prescribed antitu-
bercular treatment and ART develop TB-IRIS. Although IRIS has
been recognised for over 20 years, relatively little was known until
recently about its pathogenesis. Despite these advances in under-
standing IRIS, there remains no immune biomarker for diagnostic
or prognostic purposes. This talk will review the risk factors asso-
ciated with TB-IRIS, the challenges in studying this syndrome, and
how T lymphocytes, dysregulated cytokine responses and innate
immunity may contribute to the development of TB-IRIS.
http://dx.doi.org/10.1016/j.ijid.2014.03.575
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The role of vitamin D in tuberculosis
pathogenesis and treatment
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Tuberculosis (TB) is amajor causeofmortality, responsible foran
estimated 1.4 million deaths worldwide in 2011. The global preva-
lence of latent Mycobacterium tuberculosis infection is estimated to
be 32%, and this carries a 5–20% lifetime risk of reactivation disease.
The emergence of drug-resistant organisms necessitates the devel-
opment of new agents to enhance the response to antimicrobial
therapy for active TB. Vitamin D was used to treat TB in the pre-
antibiotic era, and its active metabolite, 1,25-dihydoxyvitamin D,
has longbeenknown toenhance the immune response tomycobac-
teria in vitro. Vitamin D deﬁciency is common in patients with
active TB, and several clinical trials have evaluated the role of
adjunctive vitamin D supplementation in its treatment. Results of
these studies are conﬂicting, reﬂecting variationbetween studies in
baseline vitaminD status of participants anddosing regimens. Vita-
min D deﬁciency is also recognised to be highly prevalent among
people with latent M. tuberculosis infection in both high- and low-
burden settings, and observational epidemiological evidence links
vitamin D deﬁciency with increased risk of both acquisition and
reactivation of latent M. tuberculosis infection. Randomised con-
trolled trials of vitamin D supplementation for the prevention of
latent infection or active disease have yet to be performed, how-
ever. The conduct of such trials is a research priority, given the
safety and low cost of vitamin D supplementation, and the signiﬁ-
cant public health consequences of positive results.
http://dx.doi.org/10.1016/j.ijid.2014.03.576
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New drugs for the treatment of tuberculosis
A. Diacon
Stellenbosch, South Africa
Prior to the introduction of chemotherapy tuberculosismanage-
ment relied upon aerotherapy, heliotherapy and good nutrition.
Tuberculosis chemotherapy began in 1944 with the introduction
